1. Introduction {#sec1}
===============

In 2013, over 7.6 million HIV-infected Africans were receiving antiretroviral drugs \[[@B1]\], including approximately 650,000 in Kenya \[[@B2]\]. Regular clinic attendance is essential for monitoring and responding to disease progression in this population; providing prophylactic medications for opportunistic infections; sustaining drug adherence; and evaluating patients for drug toxicities. Patients who miss visits are at increased risk for interruptions in antiretroviral therapy (ART), poorer immunological and virological outcomes, and higher rates of loss to follow-up and mortality \[[@B3]--[@B9]\]. They are also more likely to experience HIV progression \[[@B10]\], viral resistance to drugs \[[@B7]\], and treatment failure \[[@B7]\]. Appointment adherence early in antiretroviral treatment may be particularly critical to long-term outcomes because side effects are more likely to occur when patients are initiated on a regimen \[[@B11], [@B12]\]. Although high clinic attendance has been achieved in some resource-limited settings \[[@B13]\], there remains an urgent need for practical interventions to improve attendance to avoid drug resistance and treatment failure.

Clinic attendance may be influenced by patient social contexts and interpersonal relations with family members and within communities. Social support systems can help patients overcome structural and financial barriers to accessing care, provide a context for patients to discuss concerns about their diagnosis and treatment, and buffer against community stigma \[[@B14]\]. Studies have found patients with social support are less likely to miss a clinic visit \[[@B15]\] and report an easier time reengaging in care after an appointment has been missed \[[@B16]\]. One strategy to utilize the benefits of social support recommended by Kenya\'s National AIDS and STI Control Program (NASCOP) is engagement of a patient-nominated treatment buddy (TBy), an individual, usually a trusted family member or friend, who commits to supporting the patient on ART. The TBy may accompany the patient to the clinic and help with treatment adherence \[[@B17], [@B18]\], provide lay counsel and encouragement, and support patients in establishing healthy behaviors, such as curbing drug and alcohol use \[[@B19]\].

Previous studies of TBys have focused largely on ART adherence and HIV outcomes, with mixed results. A prospective cohort study among patients initiating ART at public facilities in South Africa found higher odds of treatment success (defined as viral load \< 400 copies/mL, CD4 ≥ 200 cells/mm^3^) at six months, one year, and two years after ART initiation among patients with TBys \[[@B20]\]. However, a randomized controlled trial (RCT) also in South Africa showed no difference in CD4 cell count or viral load at one or two years after ART initiation among patients who received directly observed ART (DOT-ART) by a TBy compared to a control group who self-administered ART \[[@B21]\], although survivorship was unexplainably better in the TBy DOT-ART group. A RCT in Nigeria found a significantly higher proportion of those in the TBy arm maintained timely ART drug pickup but showed no durable effect on CD4 cell count or mortality \[[@B22]\].

To our knowledge, only one other study has evaluated effects of a TBy on clinic attendance. A recent RCT of a TBy intervention among 174 patients attending an HIV clinic in Uganda found no difference in clinic attendance during the 28-week follow-up period \[[@B23]\]. Our study sought to reevaluate this finding within the context of HIV care in Kenya and consider the impact of the intervention separately for men and women. There is considerable evidence for gender differences in HIV health behaviors among African men and women: men have lower compliance with antiretroviral therapy \[[@B24], [@B25]\] and higher rates of attrition from care \[[@B25], [@B26]\] than women, which in turn contribute to their poorer immunological response to treatment and elevated risk of mortality \[[@B25], [@B27]\]. Although these disparities remain poorly understood, it appears that existing strategies to promote retention and adherence have been less successful in men than women. Based on these findings we sought to determine (1) the effect of TBy on clinic attendance within the first six months on ART in a cohort of HIV-infected male and female patients in Kenya and (2) whether this effect differs between men and women. In addition, because qualitative studies have also highlighted the influence of the relationship between TBys and patients \[[@B28], [@B29]\], we also sought to characterize the types of relatives and patients chosen as a TBy and explore whether choice of relative impacted clinic attendance in our study population.

2. Materials and Methods {#sec2}
========================

2.1. Study Design and Participants {#sec2.1}
----------------------------------

This was a retrospective cohort study of HIV-infected adult patients ≥15 years of age initiating ART between August 1, 2007, and December 23, 2011. The study targeted four Family AIDS Care & Education Services (FACES) supported facilities (PandiPieri, Lumumba, Family Health Options Kenya (FHOK), and Tuungane) in Kisumu County, where the prevalence of HIV (19%) is more than three times the national average for Kenya (6%) \[[@B30]\]. FHOK specializes in treatment of female sex workers, Tuungane serves pediatric and adolescent clients, and PandiPieri and Lumumba are high volume sites enrolling patients of all ages. Only patients engaged into HIV care on or after July 23, 2007 (following onset of electronic medical records capture), who had documented whether or not they had a TBy and who did not discontinue from care during the six-month post-ART follow-up were included in the study sample. This was done to establish the effect of the TBy on clinic attendance separate from the effect of the TBy on retention in care. Eligibility guidelines for ART initiation were revised during the study period from a CD4 count of ≤200 cells/mm^3^ to ≤350 cells/mm^3^ in 2011 following a change in national guidelines \[[@B31]\].

2.2. Pre-ART Clinic Procedures {#sec2.2}
------------------------------

Prior to ART initiation, the patient is counseled to disclose his/her status to one or two trusted individuals who can support his/her treatment, typically a partner, parent, daughter, sister, brother, friend, or neighbor. The patient brings the TBy to the clinic to participate in the pre-ART adherence counseling process, a series of three counseling and education sessions that cover HIV transmission and risk factors; disease progression and CD4 monitoring; purpose, benefits, and importance of ART medication and adherence; consequences of poor adherence; treatment schedule and reminder systems; and disclosure and positive living. TBys provide ongoing support for positive living and medication adherence. Patients are expected to notify the facility if there is a TBy change.

2.3. Clinic Attendance {#sec2.3}
----------------------

In Kenya, a patient\'s first six-month observation period following ART initiation typically includes a first clinic visit two to four weeks after ART initiation and monthly thereafter. Providers assess health status, adherence, drug regimen tolerance, and toxicity and modify the ARV regimen if needed. Patients are provided with ARV refills to last them until their next clinic visit, which is scheduled that day. A patient may also come to the clinic between scheduled visits as needed. TBys may attend clinic appointments with the patient or may come in the patient\'s place to pick up the drugs.

2.4. Data Collection {#sec2.4}
--------------------

Patient demographic factors, TBy status, and appointment adherence data were extracted from medical encounter forms collected during routine patient care and entered into an open source electronic medical records system database (OpenMRS system version 1.8.3). For the majority of patients (2416/2430), TBy details were extracted from the pre-ART adherence counseling form completed immediately prior to ART initiation. Another 14 patients whose TBy details could not be ascertained from the pre-ART adherence counseling form but who indicated having a TBy at the time of engagement into care were coded as having a TBy. Clinic appointment adherence was defined as completing all scheduled clinic appointments within the first six months on ART. An appointment was deemed completed if the patient was seen on or within three business days after the scheduled return date or had appeared in the clinic prior to the scheduled return date.

2.5. Measures and Statistical Analysis {#sec2.5}
--------------------------------------

The outcome was the proportion of patients who attended all clinic visits within the first six months on ART. TBy was operationalized as dichotomous for primary analyses (1 = having TBy; 0 = having no TBy) and categorical for a secondary analysis that examined clinic attendance by relationship with TBy (1 = having no TBy; 2 = partner is the TBy; 3 = another family member or friend is the TBy). Chi-square tests were performed to assess differences in demographic and clinical characteristics by TBy status. Multivariable Poisson regression with robust standard errors was used to obtain adjusted relative risks. An initial regression model with terms for TBy (dichotomous), gender, and their interaction found a significant difference in male and female response to treatment support at *p* \< 0.20; thus we decided to develop separate models for males and females. Patient\'s age, marital status, year initiated on ART, CD4 count, and clinic site were included in each multivariable model on prior belief that they might confound the TBy relationship with clinic attendance. Educational status, WHO HIV clinical stage, and months from engagement in care until ART initiation were maintained in the multivariable models if associated with clinic attendance at *p* \< 0.20 on bivariable analysis. Educational status did not meet this criterion in either men or women and was omitted from multivariable models. Data was analyzed using SAS version 9.3 (SAS Institute, Cary, NC).

2.6. Ethical Statement {#sec2.6}
----------------------

Use of the program data for research was approved by the Kenya Medical Research Institute (KEMRI) Ethical Review Committee and the Committee on Human Research (11-05348) at the University of California San Francisco. All patient data were stripped of any identifying details and identified only by a unique patient number.

3. Results and Discussion {#sec3}
=========================

3.1. Sample Characteristics {#sec3.1}
---------------------------

Of 2,430 patients who met inclusion eligibility requirements in this study, 2199 (90.5%) had a TBy ([Table 1](#tab1){ref-type="table"}). The majority of patients were female, had no more than a primary school education, and were married or partnered. Over 40% had been engaged in care for less than a month when initiated on ART and most had a CD4 cell count of \<200 (prior to change in Kenyan National Guidelines) or \<350 cells/mm^3^ at time of ART initiation. A greater proportion of males had a TBy than females, and a greater proportion of married/partnered patients had a TBy than single patients. Patients with a TBy were older. Proportion with a TBy was higher among patients at WHO stages 3 and 4 at initiation ([Table 1](#tab1){ref-type="table"}).

On univariate analysis, patients with a TBy were more likely to achieve consistent appointment adherence ([Table 2](#tab2){ref-type="table"}). The majority (60%) of patients with a TBy met all scheduled appointments during the six-month follow-up period, compared to just under half (49%) of those without a TBy \[RR = 1.23; 95% CI 1.07--1.41\]. The relationship between TBy and clinic attendance differed by gender (interaction *p* = 0.09). Equal proportions of men with and without a treatment buddy adhered to their visit schedule (57% versus 57%; RR = 1.00; 0.76--1.31). In females, 61% with a TBy consistently met scheduled appointments versus 47% without a TBy (RR = 1.31; 95% CI 1.11--1.53).

After adjusting for age, marital status, year initiated ART, months from engagement in care to ART initiation, CD4 count, WHO stage, and clinic site, females with a TBy were nearly 30% more likely to meet all scheduled appointments during the appointment follow-up period than those without one (adjusted aRR = 1.28; 95% CI 1.08--1.53; [Table 3](#tab3){ref-type="table"}). Clinic attendance showed a positive association with increasing age, with adjusted risk significantly higher among females aged 30--44 than females aged 15--29. Being in a partnership, belonging to a more recent ART initiation cohort (2011 versus 2007, 2008, or 2009), and initiating ART at an earlier clinical WHO stage were all independently associated with better clinic attendance in females. Females seen at Tuungane, PandiPieri, or FHOK were less likely to have adhered to the appointment schedule than those at Lumumba.

As with the univariate results, TBy showed no association with clinic attendance in males after adjustment for age, marital status, year initiated ART, months from engagement in care to ART initiation, CD4 count, WHO stage, and clinic site (aRR = 1.01; 95% CI 0.76--1.32; [Table 3](#tab3){ref-type="table"}). Clinic attendance was lower in males who initiated ART at WHO stages 3 and 4 compared to WHO stage 1. Clinic attendance was lower among males at Tuungane or PandiPieri compared to males at Lumumba.

3.2. Treatment Buddy Relationship to Patient {#sec3.2}
--------------------------------------------

Type of relationship with the TBy differed by patient gender (*p* \< 0.0001; data not shown). Males most commonly reported a partner/spouse (33%), brother (11%), or another family member (7%) as their TBy. Females more often reported the TBy to be a sister (17%), followed by the partner/spouse (14%) or another family member (12%). Relationship with TBy was missing for 28% of males (*n* = 217) and 28% of females (*n* = 397). On crude analysis, females whose TBy was a partner or spouse were more likely to have attended all appointments during the follow-up period than women whose TBy was another family member or friend (70% versus 61%; [Table 4](#tab4){ref-type="table"}). However, after adjustment for age, marital status, year ART initiated, CD4 count, clinic site, months from engagement in care to ART initiation, and WHO stage, there was no longer a significant difference in clinic attendance by relationship with TBy among females (aRR = 1.01; 95% CI 0.90--1.14). Similarly, on crude analysis more males with a partner or spouse as the TBy met their appointment schedule than those with another family member or friend (62% versus 52%), but there was no significance difference in clinic attendance by relationship type with the TBy after multivariable adjustment (aRR = 1.05; 95% CI 0.89--1.24).

3.3. Discussion {#sec3.3}
---------------

In this study we found better clinic attendance among women with a TBy but not men. Women with a TBy were nearly 30% more likely to have kept all appointments within the first six months on therapy than women without a TBy. Clinic attendance was not significantly different in men with or without a TBy.

For women, these findings have promising implications. Clinically, consistent attendance is essential for timely ART delivery and monitoring for toxicities and treatment failure; preventing ART interruptions is crucial because treatment lapses can result in drug resistance and increased mortality risk \[[@B32]\]. Although we could not verify that ARV adherence or clinical outcomes were better in women with more consistent attendance, because the sites participating in this study follow a protocol of prescribing ART refills to last until the next visit, missed visits represented likely gaps in treatment, placing patients at risk for poorer HIV outcomes \[[@B5]\] and higher risk of drug resistance \[[@B7]\].

For men, our finding of no TBy effect on attendance is of special concern because men show a broader pattern of poorer engagement and retention \[[@B33]\], are known to delay HIV testing and enrollment in care compared to women, and are more likely to lapse in ARV adherence and drop out of care \[[@B32], [@B34]\]. While the reasons for these disparities require further study, recent qualitative work by Chikovore et al. highlights the importance of social role definitions which place greater responsibility for family income generation on men \[[@B35]\]. Within a context of job scarcity and constant insecurity, pressure to find and maintain work may lead men to relegate health considerations. A retrospective analysis of clinical data from HIV care facilities in Kenya also found work commitments the most common reason for missed visits among men, while women were more likely to report family commitments \[[@B34]\]. With respect to our own findings, we speculate that TBys may be better able to help with competing childcare and household obligations than occupational commitments or costs of lost wages and contracts faced by workers who take time off.

Gender differences in social norms and economic standing may also influence how men and women relate to the TBy in other ways. Norms of masculinity that emphasize resilience and self-reliance discourage African men from seeking help from others when needed \[[@B36]\]. At the same time, the lower economic status of African women may lead to greater dependency on community support to surmount hardships and therefore indirectly promote better attendance behavior. A recent ethnographic study conducted in Nigeria, Tanzania, and Uganda found that HIV patients adhere to treatment guidelines to fulfill the expectations of members of their social network who provide financial or practical support \[[@B37]\]. In resource-poor environments, patients must borrow money from friends and family for food, transport to clinic, and other needs. Adherence demonstrates that the patient will use the investment responsibly and can be relied upon with future resources for care-related or other expenses. As such, we might expect TBys to exert greater influence over more marginal and economically vulnerable patients.

The protocols followed at the clinics included in this study allowed patients to self-select the TBy from among trusted family and friends. Treatment buddies participated in pre-ART preparatory education and counseling sessions with the patient and supported patients with medication reminders. TBys were also encouraged to attend clinic appointments with patients if possible and support patients with pickup of ART refills when necessary and feasible. To our knowledge, only one other study has evaluated a similar patient self-selected TBy intervention on clinic attendance, a recent RCT led by Kunutsor et al. among 174 patients on ART at a hospital in Uganda \[[@B23]\]. That study, which pooled together results for men and women, found a weak but not statistically significant trend towards better clinic attendance in the TBy group compared to the standard-of-care group. It may be that the larger sample included in this study allowed for better detection of differences between groups or that the decision to stratify by gender highlighted an effect among women masked in the earlier trial.

Previous research has shown that patients and providers choose treatment buddies who are confidantes and able to influence health-related decision-making \[[@B25], [@B28], [@B37]\]. Trust, geographic proximity to the TBy, emotional availability, reciprocity, and material resources are all important features of the treatment buddy-patient relationship \[[@B29]\]. In our study, most patients selected a family member to serve as a TBy. Women most often chose a sister, perhaps because they perceived sisters to be more supportive than other family members \[[@B38]\]. Men were more than twice as likely to report the partner as the TBy than women, probably because they faced less risk of partner violence or stigma. Relationship type did not however appear to influence the effect of the TBy on clinic attendance in either gender. For women, clinic attendance was higher whether they chose the partner or another family member or friend. In men, clinic attendance was not significantly different whether they chose the partner, another family member or friend, or no TBy.

Strengths of our study include a large, representative cohort of patients at multiple HIV care settings in Kenya. This is the first study to our knowledge to examine the effectiveness of TBys as an intervention in Kenya and the only large-scale study to examine type of relationship to the TBy among HIV patients in sub-Saharan Africa. A study limitation was that it was based on observational data and may be subject to unmeasured confounding. In particular, because of the self-nominated nature of the TBy intervention at FACES-supported clinics, patients with a TBy may have generally stronger social connections and greater support within their social network than those without a TBy. Thus the TBy may serve as a marker for social capital. Patients initiated on ART without a TBy also reflect an unusual exception to Kenyan guidelines that encourage the selection of a TBy and may therefore differ from the general population of new patients on ART. For example, they may be more disadvantaged or have more clinically advanced illness. Nevertheless, we were able to control for a number of sociodemographic and disease markers to help account for some of these differences. A second limitation of this study was that TBy status could only be ascertained for the 48% of patients initiated on ART during the study period for whom pre-ART adherence counseling data was available in the administrative database. Third, we were not able to directly associate clinic attendance with ARV adherence or clinical outcomes. However, the relationship between clinic attendance and ART adherence and outcomes has been firmly established \[[@B3]--[@B5], [@B8]\]. Finally, we only examined attendance patterns during the first six months on ART. One- and two-year follow-up are needed to assess longer-term durability of our findings.

4. Conclusions {#sec4}
==============

In summary, clinic attendance was higher during the first six months of ART among women with TBys but not men. These results support TBys to help women achieve ART success in resource-poor settings; alternate strategies to bolster TBy benefits are needed for men. Specialized trainings for TBys and caregiver support groups may further enhance the impact of TBys on adherence and health outcomes for all patients on ART.
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###### 

Sample characteristics (*n* = 2430)^*∗*^.

  Characteristics                                            TBy (*n* = 2199)   No TBy (*n* = 231)   *p* value^*∗∗*^
  ---------------------------------------------------------- ------------------ -------------------- -----------------
  Gender                                                                                             \<0.0001
   Male                                                      770 (94.8)         42 (5.2)              
   Female                                                    1429 (88.3)        189 (11.7)            
  Age (years; enrollment), median (IQR)                      32 (27--39)        30 (25--35)          \<0.0001
   15--29                                                    852 (88.3)         113 (11.7)            
   30--44                                                    1038 (90.7)        107 (9.3)             
   45+                                                       309 (96.6)         11 (3.4)              
  Education level (enrollment)                                                                       0.05
   None                                                      57 (98.3)          1 (1.7)               
   Primary                                                   1118 (91.2)        108 (8.8)             
   Secondary                                                 665 (89.4)         79 (10.6)             
   College                                                   164 (93.7)         11 (6.3)              
   Missing                                                   195 (85.9)         32 (14.1)             
  Marital status (enrollment)                                                                        \<0.0001
   Single                                                    894 (87.9)         123 (12.1)            
   Partnered                                                 1076 (93.1)        80 (6.9)              
   Missing                                                   229 (89.1)         28 (10.9)             
  Children in household (enrollment)                                                                 0.11
   0                                                         469 (90.9)         47 (9.1)              
   1                                                         447 (91.4)         42 (8.6)              
   2                                                         457 (88.1)         62 (12.0)             
   3+                                                        563 (92.1)         48 (7.9)              
   Missing                                                   263 (89.2)         32 (10.9)             
  Year ART initiated                                                                                 \<0.0001
   2007                                                      31 (79.5)          8 (20.5)              
   2008                                                      242 (80.9)         57 (19.1)             
   2009                                                      513 (91.3)         49 (8.7)              
   2010                                                      749 (92.5)         61 (7.5)              
   2011                                                      664 (92.2)         56 (7.8)              
  Months from enrollment to ART initiation, median (IQR)     1 (0--3)           1 (0--6)             0.03
   \<1                                                       964 (91.7)         87 (8.3)              
   1-2                                                       530 (91.7)         48 (8.3)              
   2-3                                                       131 (86.2)         21 (13.8)             
   \>3                                                       574 (88.4)         75 (11.6)             
  CD4 count (cells/mm^3^; ART initiation), median (IQR)^†^   180 (82--260)      189 (113--280)       0.52
   \>350                                                     155 (88.6)         20 (11.4)             
   200--350                                                  797 (90.2)         87 (9.8)              
   \<200                                                     1207 (91.0)        119 (9.0)             
  WHO stage (ART initiation)^†^                                                                      0.03
   1                                                         526 (88.9)         66 (11.2)             
   2                                                         697 (88.7)         89 (11.3)             
   3                                                         809 (92.7)         64 (7.3)              
   4                                                         156 (92.9)         12 (7.1)              
  Clinic site                                                                                        \<0.0001
   Lumumba                                                   993 (90.8)         101 (9.2)             
   Tuungane                                                  73 (97.3)          2 (2.7)               
   PandiPieri                                                1011 (94.9)        54 (5.1)              
   FHOK                                                      122 (62.2)         74 (37.8)            
  Retention during first 6 months on ART                                                             0.001
   Missed ≥1 visits                                          890 (88.2)         119 (11.8)            
   Missed no visits                                          1309 (92.1)        112 (7.9)             

  ^*∗*^ *n* (%) shown unless otherwise indicated.

^*∗∗*^Significance tests based on nonmissing values.

^†^There were missing data for the following predictors:

CD4 count: 45 patients; 40 with treatment buddy and 5 without treatment buddy.

WHO stage: 10 patients, all with treatment buddy.

###### 

Unadjusted relative risks for factors associated with clinic attendance during the first six months on ART, overall, and by gender.

  Predictor             Total (*n* = 2430)   Male (*n* = 812)   Female (*n* = 1618)                                                                                      
  --------------------- -------------------- ------------------ --------------------- ----- ------ ------------------------------------------------------- ------ ------ -------------------
  Has treatment buddy                                                                                                                                                     
   Yes                  1309                 59.5               1.23 (1.07--1.41)     770   57.1   1.00 (0.76--1.31)                                       1429   60.8   1.31 (1.11--1.53)
   No                   112                  48.5               REF                   42    57.1   REF                                                     189    46.6   REF
                                                                                                   Treatment buddy × gender interaction *p* value = 0.09                 

###### 

Adjusted relative risks for factors associated with clinic attendance during the first six months on ART, by gender.

  Predictor                                          Male (*n* = 716)   Female (*n* = 1405)                                                                    
  -------------------------------------------------- ------------------ --------------------- ------ ------------ ---------- ------ ------ ------ ------------ ----------
  Has treatment buddy                                                                                                                                           
   Yes                                               679                57.6                  1.01   0.76--1.32   0.97       1243   60.6   1.28   1.08--1.53   0.005
   No                                                37                 59.5                  REF                            162    45.1   REF                  
  Age                                                                                                                                                           
   15--29                                            173                56.7                  REF                            681    54.9   REF                  
   30--44                                            394                56.6                  0.99   0.85--1.15   0.90       599    62.4   1.12   1.03--1.22   0.01
   45+                                               149                61.7                  1.05   0.87--1.25   0.62       125    62.4   1.14   0.98--1.33   0.08
  Marital status                                                                                                                                                
   Single                                            191                53.9                  REF                            798    54.0   REF                  
   Partnered                                         525                59.1                  1.02   0.89--1.18   0.75       607    65.1   1.10   1.01--1.20   0.04
  Year ART initiated                                                                                                                                            
   2007                                              6                  16.7                  0.20   0.03--1.24   0.08       26     42.3   0.62   0.39--0.99   0.04
   2008                                              78                 59.0                  0.83   0.66--1.03   0.09       151    54.3   0.80   0.68--0.94   0.007
   2009                                              163                60.7                  0.97   0.82--1.14   0.71       318    53.8   0.83   0.73--0.94   0.003
   2010                                              245                57.1                  0.90   0.77--1.05   0.17       479    61.0   0.94   0.85--1.04   0.24
   2011                                              224                56.7                  REF                            431    62.7   REF                  
  Months from engagement in care to ART initiation                                                                                                              
   \<1                                               354                52.5                  REF                            581    58.5   REF                  
   1-2                                               188                60.6                  1.07   0.92--1.23   0.37       315    55.9   0.92   0.82--1.04   0.18
   2-3                                               42                 61.9                  1.12   0.85--1.48   0.40       96     51.0   0.88   0.72--1.08   0.21
   \>3                                               132                65.9                  1.12   0.94--1.32   0.20       413    63.2   1.04   0.93--1.16   0.45
  CD4 count                                                                                                                                                     
   \>350                                             38                 65.8                  1.09   0.84--1.40   0.51       115    56.5   0.92   0.77--1.09   0.32
   200--350                                          214                63.1                  1.04   0.90--1.20   0.61       565    63.4   1.05   0.95--1.16   0.36
   \<200                                             464                54.5                  REF                            725    55.6   REF                  
  WHO stage                                                                                                                                                     
   1                                                 151                67.6                  REF                            365    66.0   REF                  
   2                                                 194                61.9                  0.93   0.80--1.09   0.36       506    58.1   0.91   0.83--1.01   0.09
   3                                                 308                51.3                  0.80   0.69--0.93   0.003      454    57.1   0.91   0.81--1.01   0.08
   4                                                 62                 51.6                  0.74   0.57--0.96   0.03       80     40.0   0.65   0.49--0.85   0.002
  Clinic site                                                                                                                                                   
   Lumumba                                           345                72.5                  REF                            577    71.4   REF                  
   Tuungane                                          22                 45.5                  0.58   0.36--0.92   0.02       41     31.7   0.44   0.28--0.69   0.0003
   PandiPieri                                        349                43.8                  0.58   0.51--0.67   \<0.0001   610    52.3   0.69   0.63--0.76   \<0.0001
   FHOK                                              na                 na                    na     na           na         177    46.3   0.68   0.57--0.81   \<0.0001

###### 

Adjusted relative risks for factors associated with clinic attendance during the first six months on ART including relationship to TBy, by gender.

  Predictor                      Male   Female                                                                            
  ------------------------------ ------ -------- ------------------- ------------------- ----- ------ ------------------- -------------------
  Treatment buddy relationship                                                                                             
   Partner/spouse                250    62.4     1.18 (1.02--1.36)   1.05 (0.89--1.24)   198   69.7   1.14 (1.03--1.27)   1.01 (0.90--1.14)
   Other                         303    51.8     REF                 REF                 834   60.9   REF                 REF
   None                          42     57.1     1.08 (0.82--1.44)   1.03 (0.77--1.37)   189   46.6   0.76 (0.65--0.90)   0.75 (0.62--0.90)

^*∗*^Adjusted for age, marital status, year ART initiated, CD4 count, clinic site, months from engagement in care to ART initiation, and WHO stage.

[^1]: Academic Editor: Soraya Seedat
